High tech is an essential tool to combat COVID-19. Recently, companies in Qingdao International Economic Cooperation Zone including BGI Qingdao and Realbio have been giving out “intelligence assistance for epidemic control” by leveraging their hardcore technology capabilities.
BGI Qingdao shares supercomputing power by opening its bioinformation platform
Recently, a statement issued on the WeChat account of BGI Qingdao has drawn wide attention. As an industrial leader in gene sequencing, BGI Qingdao has unique technological strengths in bioinformation analysis. The freely shared contents this time include bioinformation analysis software platform, hardware storage, resources that support parallel computing of up to 5000 CPUs and specialized bioinformation analysis services. For those researchers who are making full use of every minute to fight against COVID-2019, these shared resources would definitely be a great help for their research.
Researchers or institutes who are interested may contact BGI Qingdao via the E-mail: yangxianwei@genomics.cn.
Realbio provides free nucleic acid testing to help ensure safe operation resumption
Nucleic acid testing is an important diagnostic tool for novel coronavirus test. As the first test that should be taken on suspected cases, it is very helpful for timely detection of early-stage COVID-19 infections. Recently, Qingdao International Economic Cooperation Zone Administrative Committee received a letter from Qingdao Realbio Precision Medical Test Laboratory which says the company is willing to provide free nucleic acid testing for working staff and companies in the zone.
It is learnt that Qingdao Realbio Precision Medical Test Laboratory is the first such lab established in Qingdao International Economic Cooperation Zone. Its construction started in December 2018. It is designed as the North China Base for Test Services Headquarters of Shanghai Realbio Technology Co., Ltd.
According to the company, Qingdao Realbio Precision Medical Test Co., Ltd has passed the external quality assessment of nucleic acid testing for COVID-19 by Shanghai Center for Clinical Laboratory (CNAS PT0025) and Shanghai Quality Control Center for Clinical Laboratory.
